CaliciX™ Max is a high-strength systemic antiviral capsule formulated for cats suffering from severe, refractory, or high-viral-load feline calicivirus (FCV) disease, where standard-dose therapy may be insufficient.

CaliciX™ Max delivers 30 mg of EIDD-1931 per capsule, enabling veterinarians to achieve higher systemic antiviral suppression with fewer capsules compared to CaliciX™. It is intended for step-up therapy in advanced, severe, or poorly responsive feline calicivirus (FCV) cases.

CaliciX™ Max may be considered under veterinary supervision when a cat has: • Severe oral or oropharyngeal disease • Refractory FCGS or post-extraction stomatitis • High systemic viral burden • Poor response to 2-4mg/kg dosing • Larger body weight requiring higher per-dose exposure

CaliciX™ Max is formulated to support cats with severe FCV-associated disease, including: • Severe feline chronic gingivostomatitis (FCGS) • Caudal stomatitis with extensive inflammation • Deep lingual ulceration (viral glossitis) • Multifocal oral ulceration • Virulent systemic feline calicivirus (VS-FCV)

Yes, CaliciX™ Max is designed for veterinarian-directed use in such severe presentations, alongside intensive supportive care.

No. CaliciX™ Max is not an antibiotic. It is a direct-acting antiviral designed to suppress FCV viral replication. Antibiotics may still be used separately to manage secondary bacterial infections when indicated.

EIDD-1931 interferes with viral RNA replication by inducing lethal mutagenesis in RNA viruses. This mechanism: • Does not rely on viral proteases • Has a high genetic barrier to resistance • Works independently of host immune status

CaliciX™ Max may be used as part of an extended management plan in cats with chronic or refractory feline calicivirus (FCV) where ongoing antiviral control is clinically indicated. Treatment duration, dose adjustments, and monitoring should always be determined by a licensed veterinarian based on the individual patient’s response and overall health status.

No. CaliciX™ Max is intended to be part of a comprehensive veterinary treatment plan, which may include dental procedures, pain control, nutritional support, and other therapies as needed.

No. CaliciX™ Max is not the same as human molnupiravir. It contains EIDD-1931, the active antiviral metabolite of molnupiravir—the form that directly exerts antiviral activity. Published research indicates that EIDD-1931 demonstrates significantly higher antiviral potency than molnupiravir, which is a prodrug requiring metabolic conversion. CaliciX™ Max is formulated specifically for veterinary use in cats, with dosing, capsule size, and clinical intent designed for feline patients rather than humans.

It may not be suitable for: • Pregnant or breeding cats • Cats with significant hepatic or renal disease CaliciX™ Max is intended for veterinary-supervised use only.

The 30 mg strength allows veterinarians to: • Achieve higher antiviral exposure • Reduce capsule burden in large or severe cases • Improve dosing accuracy and compliance This makes it suitable for advanced or high-risk FCV disease.

Yes. CaliciX™ Max is intended for off-label veterinary use under professional supervision, with informed owner consent.